Anemocyte is pleased to announce its participation in the Cell & Gene Meeting on the Med 2025, taking place from April 15th to 17th at the Rome Cavalieri in Rome. The event will be held in a hybrid format, allowing attendees to choose between in-person and virtual participation.
The Cell & Gene Meeting on the Med is a premier conference in the field of cell and gene therapies, offering networking opportunities and insights into the latest industry trends. The 2025 edition will welcome nearly 600 industry professionals, featuring over 50 company presentations and 15+ panel discussions and fireside chats.
The Cell & Gene Meeting on the Med 2025 will offer three days of insights and networking dedicated to advanced therapies.
The event will also include thematic workshops and partnering meetings, fostering new synergies between companies, investors, and institutions.
Anemocyte’s participation underscores its commitment to expanding its presence in the global market and fostering international collaborations in the field of biotechnological therapies. The company provides end-to-end solutions, from R&D to GMP-compliant manufacturing, specializing in:
The event’s seminars and workshops will offer in-depth insights into the latest innovations, regulatory updates, and emerging trends in biopharmaceutical production. These sessions present a valuable opportunity for industry professionals to stay informed and build meaningful connections.
By attending the Cell & Gene Meeting on the Med 2025, Anemocyte will have the opportunity to connect with suppliers, innovators, and key industry leaders, facilitating strategic partnerships and unlocking new business opportunities. The event serves as an ideal platform to engage with the European pharmaceutical ecosystem, establish key relationships, and explore market prospects.
For companies aiming to expand their presence in the European pharmaceutical market, particularly in the advanced therapies sector, the Cell & Gene Meeting on the Med is an unmissable event.
